Systemic Lupus Erythematosus – Epidemiology – Epidemiology Dashboard

Clarivate Epidemiology’s coverage of SLE comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of SLE for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.

Clarivate Epidemiology’s SLE forecast will answer the following questions:

  • How many people, regardless of diagnosis status, have SLE?
  • How does diagnosis status and drug-treated status differ between higher-income countries?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of SLE over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate Epidemiology provides at least 10 years of forecast data for the following SLE patient populations:

  • Diagnosed incidence of SLE.
  • Diagnosed prevalence of SLE.
  • Diagnosed prevalence of SLE by renal involvement status.
  • Diagnosed prevalence of SLE by drug-treatment status.

Note: Coverage may vary by country and region.

launch Related Market Assessment Reports